Innate gamma/delta T-cells during HIV infection: Terra relatively incognita in novel vaccination strategies?

AIDS Reviews

Volumn 13, Issue 1, 2011, Pages 3-12

  Agrati, Chiara ^a   D'Offizi, Gianpiero ^a   Gougeon, Marie Lise ^b   Malkovsky, Miroslav ^c   Sacchi, Alessandra ^a   Casetti, Rita ^a   Bordoni, Veronica ^a   Cimini, Eleonora ^a   Martini, Federico ^a  

^a NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^b INSTITUT PASTEUR   (France)

^c UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Antiviral response; Early HIV infection; Innate immunity; Mucosal immunity

Indexed keywords

ALPHA DEFENSIN; BETA 2 MICROGLOBULIN; BETA CHEMOKINE; BISPHOSPHONIC ACID DERIVATIVE; GAMMA INTERFERON; GLYCOPROTEIN GP 120; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; IMMUNOMODULATING AGENT; INTERLEUKIN 15; INTERLEUKIN 2; ISOPENTENYL DIPHOSPHATE; LYMPHOCYTE ANTIGEN RECEPTOR; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 2; NEOPTERIN; PROTEIN KINASE C; PROTEIN P27; RANTES; T LYMPHOCYTE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; ZOLEDRONIC ACID; HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADAPTIVE IMMUNITY; ADJUVANT THERAPY; ALPHA CHAIN; ANTIGEN RECOGNITION; ANTIGEN SPECIFICITY; ANTIVIRAL ACTIVITY; APOPTOSIS; ARTICLE; BETA CHAIN; BLOOD TRANSFUSION; CARCINOMA; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELL ACTIVATION; CELL EXPANSION; CELL LOSS; CELL MATURATION; CLONAL ANERGY; CYTOKINE RELEASE; CYTOTOXICITY; DELTARETROVIRUS INFECTION; DENDRITIC CELL; DISEASE COURSE; DRUG TARGETING; EHRLICHIOSIS; EUKARYOTIC CELL; GAMMA DELTA T LYMPHOCYTE; GRAFT VERSUS LEUKEMIA EFFECT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN HERPESVIRUS 6; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNITY; IMMUNOCOMPETENT CELL; IMMUNOREGULATION; IMMUNOSURVEILLANCE; IN VIVO STUDY; INNATE IMMUNITY; LAMINA PROPRIA; LYMPH NODE; LYMPHOCYTE ACTIVATION; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; LYMPHOMA; MIXED INFECTION; MOLECULAR INTERACTION; MONOCYTE; MUCOSAL IMMUNITY; MYELOMA; NATURAL KILLER CELL; NEUTROPHIL; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PERIPHERAL LYMPHOCYTE; PHAGOCYTE; PROTEIN EXPRESSION; PROTEIN SECRETION; SIMIAN IMMUNODEFICIENCY VIRUS; SURVIVAL; T LYMPHOCYTE RECEPTOR GENE; TH1 CELL; TH17 CELL; TUBERCULOSIS; VIRUS REPLICATION; IMMUNOLOGY; METHODOLOGY; REVIEW; T LYMPHOCYTE SUBPOPULATION; VACCINATION;

AIDS VACCINES; HIV INFECTIONS; HUMANS; IMMUNITY, INNATE; T-LYMPHOCYTE SUBSETS; VACCINATION;

EID: 79960641911     PISSN: 11396121     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (97)

1. Johnston M., Fauci A. An HIV vaccine-challenges and prospects. N Engl J Med. 2008;359:888-890
2. Dolin R. HIV vaccine trial results--an opening for further research. N Engl J Med. 2009;361:2279-2280
3. McMichael A., Borrow P., Tomaras G., Goonetilleke N., Haynes B. The immune response during acute HIV-1 infection:Clues for vaccine development. Nat Rev Immunol. 2010;10:11-23.
4. Hayday A. Gammadelta T cells and the lymphoid stress-surveillance response. Immunity. 2009;31:184-196
5. Poccia F., Wallace M., Colizzi V., Malkovsky M. Possible protective and pathogenic roles of gamma delta T lymphocytes in HIV-infections (Review). Int J Mol Med. 1998;1:409-413
6. Poccia F., Gougeon M., Bonneville M., et al. Innate T-cell immunity to nonpeptidic antigens. Immunol Today. 1998;19:253-256 (Pubitemid 28300192)
7. Hofer U., Speck R. Disturbance of the gut-associated lymphoid tissue is associated with disease progression in chronic HIV infection. Semin Immunopathol. 2009;31:257-266
8. Shacklett B. Mucosal immunity to HIV:A review of recent literature. Curr Opin HIV AIDS. 2008;3:541-547
9. Shattock R., Haynes B., Pulendran B., Flores J., Esparza J. Improving defences at the portal of HIV entry:Mucosal and innate immunity. PLoS Med. 2008;5:e81.
10. Heilig J., Tonegawa S. Diversity of murine gamma genes and expression in fetal and adult T lymphocytes. Nature. 1986;322:836-840 (Pubitemid 16055256)
11. Chien Y., Iwashima M., Wettstein D., et al. T-cell receptor delta gene rearrangements in early thymocytes. Nature. 1987;330:722-727 (Pubitemid 18015673)
12. Born W., Miles C., White J., et al. Peptide sequences of T-cell receptor delta and gamma chains are identical to predicted X and gamma proteins. Nature. 1987;330:572-574 (Pubitemid 17164354)
13. Hayday A. [gamma][delta] cells:A right time and a right place for a conserved third way of protection. Annu Rev Immunol. 2000;18: 975-1026. (Pubitemid 30365402)
14. Gober H., Kistowska M., Angman L., et al. Human T cell receptor gammadelta cells recognize endogenous mevalonate metabolites in tumor cells. J Exp Med. 2003;197:163-168 (Pubitemid 36152311)
15. Parker C., Groh V., Band H., et al. Evidence for extrathymic changes in the T cell receptor gamma/delta repertoire. J Exp Med. 1990;171: 1597-1612 (Pubitemid 20167553)
16. Martino A., Poccia F. Gamma delta T cells and dendritic cells:Close partners and biological adjuvants for new therapies. Curr Mol Med. 2007;7:658-673 (Pubitemid 350201666)
17. Conti L., Casetti R., Cardone M., et al. Reciprocal activating interaction between dendritic cells and pamidronate-stimulated gammadelta T cells:Role of CD86 and inflammatory cytokines. J Immunol. 2005;174:252-260 (Pubitemid 40007411)
18. Agrati C., Cimini E., Sacchi A., et al. Activated V gamma 9V delta 2 T cells trigger granulocyte functions via MCP-2 release. J Immunol. 2009; 182:522-529
19. Evans P., Enders P., Yin C., et al. In vitro stimulation with a non-peptidic alkylphosphate expands cells expressing Vgamma2-Jgamma1.2/Vdelta2 T-cell receptors. Immunology. 2001;104:19-27.
20. Mingari M., Varese P., Bottino C., et al. Clonal analysis of CD4-CD8- human thymocytes expressing a T cell receptor gamma/delta chain. Direct evidence for the de novo expression of CD8 surface antigen and of cytolytic activity against tumor targets. Eur J Immunol. 1988;18:1831-1834 (Pubitemid 19011595)
21. Qin G., Mao H., Zheng J., et al. Phosphoantigen-expanded human gammadelta T cells display potent cytotoxicity against monocyte-derived macrophages infected with human and avian influenza viruses. J Infect Dis. 2009;200:858-865
22. Van de Griend R., Gravekamp C., Bolhuis R. Human CD3+4-8- TCR alpha beta- gamma+ blood T cells, their lytic potential against tumor cells, and their recognition using WT31 monoclonal antibody. Transplant Proc. 1988;20:332-335
23. Poccia F., Cipriani B., Vendetti S., et al. CD94/NKG2 inhibitory receptor complex modulates both anti-viral and anti-tumoral responses of polyclonal phosphoantigen-reactive V gamma 9V delta 2 T lymphocytes. J Immunol. 1997;159:6009-6017 (Pubitemid 127471537)
24. Halary F., Peyrat M., Champagne E., et al. Control of self-reactive cytotoxic T lymphocytes expressing gamma delta T cell receptors by natural killer inhibitory receptors. Eur J Immunol. 1997;27:2812-2821 (Pubitemid 27478348)
25. Bakker A., Phillips J., Figdor C., Lanier L. Killer cell inhibitory receptors for MHC class I molecules regulate lysis of melanoma cells mediated by NK cells, gamma delta T cells, and antigen-specific CTL. J Immunol. 1998; 160:5239-5245 (Pubitemid 28267808)
26. Janis E., Kaufmann S., Schwartz R., Pardoll D. Activation of gamma delta T cells in the primary immune response to Mycobacterium tuberculosis. Science. 1989;244:713-716 (Pubitemid 19147684)
27. Caldwell C., Everett E., McDonald G., Yesus Y., Roland W. Lymphocytosis of gamma/delta T cells in human ehrlichiosis. Am J Clin Pathol. 1995; 103:761-766
28. Tanaka Y., Sano S., Nieves E., et al. Nonpeptide ligands for human gamma delta T cells. Proc Natl Acad Sci USA. 1994;91:8175-8179 (Pubitemid 24253909)
29. Tanaka Y., Morita C., Tanaka Y., et al. Natural and synthetic non-peptide antigens recognized by human gamma delta T cells. Nature. 1995; 375:155-158
30. Tanaka Y., Kobayashi H., Terasaki T., et al. Synthesis of pyrophosphatecontaining compounds that stimulate Vgamma2Vdelta2 T cells:Application to cancer immunotherapy. Med Chem. 2007;3:85-99. (Pubitemid 46062346)
31. Morita C., Beckman E., Bukowski J., et al. Direct presentation of nonpeptide prenyl pyrophosphate antigens to human gamma delta T cells. Immunity. 1995;3:495-507.
32. Autran B., Triebel F., Katlama C., et al. T cell receptor gamma/delta+ lymphocyte subsets during HIV infection. Clin Exp Immunol. 1989; 75:206-210 (Pubitemid 19074247)
33. Hermier F., Comby E., Delaunay A., et al. Decreased blood TcR gamma delta+ lymphocytes in AIDS and p24-antigenemic HIV-1-infected patients. Clin Immunol Immunopathol. 1993;69:248-250 (Pubitemid 23319394)
34. Chia W., Freedman J., Li X., et al. Programmed cell death induced by HIV type 1 antigen stimulation is associated with a decrease in cytotoxic T lymphocyte activity in advanced HIV type 1 infection. AIDS Res Hum Retroviruses. 1995;11:249-256
35. Norazmi M., Arifin H., Jamaruddin M. Increased level of activated gamma delta lymphocytes correlates with disease severity in HIV infection. Immunol Cell Biol. 1995;73:245-248
36. Li H., Peng H., Ma P., et al. Association between Vgamma2Vdelta2 T cells and disease progression after infection with closely related strains of HIV in China. Clin Infect Dis. 2008;46:1466-1472 (Pubitemid 351589954)
37. Poccia F., Boullier S., Lecoeur H., et al. Peripheral V gamma 9/V delta 2 T cell deletion and anergy to nonpeptidic mycobacterial antigens in asymptomatic HIV-1-infected persons. J Immunol. 1996;157:449-461 (Pubitemid 26190580)
38. Montesano C., Gioia C., Martini F., et al. Antiviral activity and anergy of gammadeltaT lymphocytes in cord blood and immuno-compromised host. J Biol Regul Homeost Agents. 2001;15:257-264 (Pubitemid 32994575)
39. Wallace M., Scharko A., Pauza C., et al. Functional gamma delta T-lymphocyte defect associated with human immunodeficiency virus infections. Mol Med. 1997;3:60-71. (Pubitemid 27142525)
40. Gan Y., Pauza C., Malkovsky M. Gamma delta T cells in rhesus monkeys and their response to simian immunodeficiency virus (SIV) infection. Clin Exp Immunol. 1995;102:251-255
41. Malkovsky M., Wallace M., Fournie J., et al. Alternative cytotoxic effector mechanisms in infections with immunodeficiency viruses:Gammadelta T lymphocytes and natural killer cells. AIDS. 2000;14(Suppl 3): S175-S186
42. Garcia V., Sieling P., Gong J., et al. Single-cell cytokine analysis of gamma delta T cell responses to nonpeptide mycobacterial antigens. J Immunol. 1997;159:1328-1335 (Pubitemid 127484111)
43. Boullier S., Poquet Y., Debord T., Fournie J., Gougeon M. Regulation by cytokines (IL-12, IL-15, IL-4 and IL-10) of the Vgamma9Vdelta2 T cell response to mycobacterial phosphoantigens in responder and anergic HIV-infected persons. Eur J Immunol. 1999;29:90-99 (Pubitemid 29043526)
44. Martini F., Urso R., Gioia C., et al. gammadelta T-cell anergy in human immunodeficiency virus-infected persons with opportunistic infections and recovery after highly active antiretroviral therapy. Immunology. 2000;100:481-486 (Pubitemid 30608501)
45. Gioia C., Agrati C., Casetti R., et al. Lack of CD27-CD45RA-V gamma 9V delta 2+ T cell effectors in immunocompromised hosts and during active pulmonary tuberculosis. J Immunol. 2002;168:1484-1489 (Pubitemid 34094523)
46. Sacchi A., Tempestilli M., Turchi, F. et al. CD3zeta down-modulation may explain Vgamma9Vdelta2 T lymphocyte anergy in HIV-infected patients. J Infect Dis. 2009;199:432-436
47. Valitutti S., Muller S., Salio M., Lanzavecchia A. Degradation of T cell receptor (TCR)-CD3-zeta complexes after antigenic stimulation. J Exp Med. 1997;185:1859-1864 (Pubitemid 27242207)
48. Isomaki P., Panesar M., Annenkov A., et al. Prolonged exposure of T cells to TNF down-regulates TCR zeta and expression of the TCR/CD3 complex at the cell surface. J Immunol. 2001;166:5495-5507 (Pubitemid 32374171)
49. Stacey A., Norris P., Qin L., et al. Induction of a striking systemic cytokine cascade prior to peak viremia in acute human immunodeficiency virus type 1 infection, in contrast to more modest and delayed responses in acute hepatitis B and C virus infections. J Virol. 2009;83:3719-3733
50. Martini F., Poccia F., Goletti D., et al. Acute human immunodeficiency virus replication causes a rapid and persistent impairment of Vgamma9Vdelta2 T cells in chronically infected patients undergoing structured treatment interruption. J Infect Dis. 2002;186:847-850 (Pubitemid 35013440)
51. Enders P., Yin C., Martini F., et al. HIV-mediated gammadelta T cell depletion is specific for Vgamma2+ cells expressing the Jgamma1.2 segment. AIDS Res Hum Retroviruses. 2003;19:21-29 (Pubitemid 36398740)
52. Bordon J., Evans P., Propp N., et al. Association between longer duration of HIV-suppressive therapy and partial recovery of the V gamma 2 T cell receptor repertoire. J Infect Dis. 2004;189:1482-1486 (Pubitemid 38543598)
53. Hebbeler A., Propp N., Cairo C., et al. Failure to restore the Vgamma2- Jgamma1.2 repertoire in HIV-infected men receiving highly active antiretroviral therapy (HAART). Clin Immunol. 2008;128:349-357
54. Riedel D., Sajadi M., Armstrong C., et al. Natural viral suppressors of HIV-1 have a unique capacity to maintain gammadelta T cells. AIDS. 2009;23:1955-1964
55. Lehner T., Mitchell E., Bergmeier L., et al. The role of gammadelta T cells in generating antiviral factors and beta-chemokines in protection against mucosal simian immunodeficiency virus infection. Eur J Immunol. 2000;30:2245-2256
56. Poccia F., Battistini L., Cipriani B., et al. Phosphoantigen-reactive Vgamma9Vdelta2 T lymphocytes suppress in vitro human immunodeficiency virus type 1 replication by cell-released antiviral factors including CC chemokines. J Infect Dis. 1999;180:858-861 (Pubitemid 29411378)
57. Wallace M., Gan Y., Pauza C., Malkovsky M. Antiviral activity of primate gamma delta T lymphocytes isolated by magnetic cell sorting. J Med Primatol. 1994;23:131-135
58. Wallace M., Bartz S., Chang W., et al. Gamma delta T lymphocyte responses to HIV. Clin Exp Immunol. 1996;103:177-184
59. Biswas P., Ferrarini M., Mantelli B., et al. Double-edged effect of Vgamma9/ Vdelta2 T lymphocytes on viral expression in an in vitro model of HIV-1/mycobacteria co-infection. Eur J Immunol. 2003;33:252-263 (Pubitemid 36157663)
60. Kosub D., Lehrman G., Milush J., et al. Gamma/Delta T-cell functional responses differ after pathogenic human immunodeficiency virus and nonpathogenic simian immunodeficiency virus infections. J Virol. 2008; 82:1155-1165
61. Kunzmann V., Bauer E., Wilhelm M. Gamma/delta T-cell stimulation by pamidronate. N Engl J Med. 1999;340:737-738
62. Gougeon M., Malkovsky M., Casetti R., Agrati C., Poccia F. Innate T cell immunity to HIV-infection. Immunotherapy with phosphocarbohydrates, a novel strategy of immune intervention? Vaccine. 2002; 20:1938-1941 (Pubitemid 34450791)
63. Kunzmann V., Bauer E., Feurle J., et al. Stimulation of gammadelta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma. Blood. 2000;96:384-392 (Pubitemid 30463353)
64. Sicard H., Ingoure S., Luciani B., et al. In vivo immunomanipulation of V gamma 9V delta 2 T cells with a synthetic phosphoantigen in a preclinical nonhuman primate model. J Immunol. 2005;175:5471-5480 (Pubitemid 41456434)
65. Beetz S., Marischen L., Kabelitz D., Wesch D. Human gamma delta T cells:Candidates for the development of immunotherapeutic strategies. Immunol Res. 2007;37:97-111. (Pubitemid 47344127)
66. Dieli F., Vermijlen D., Fulfaro F., et al. Targeting human {gamma}delta} T cells with zoledronate and interleukin-2 for immunotherapy of hormonerefractory prostate cancer. Cancer Res. 2007;67:7450-7457 (Pubitemid 47206575)
67. Wilhelm M., Kunzmann V., Eckstein S., et al. Gammadelta T cells for immune therapy of patients with lymphoid malignancies. Blood. 2003; 102:200-206 (Pubitemid 36759655)
68. Godder K., Henslee-Downey P., Mehta J., et al. Long term disease-free survival in acute leukemia patients recovering with increased gammadelta T cells after partially mismatched related donor bone marrow transplantation. Bone Marrow Transplant. 2007;39:751-757 (Pubitemid 46901973)
69. Caccamo N., Meraviglia S., Cicero G., et al. Aminobisphosphonates as new weapons for gammadelta T Cell-based immunotherapy of cancer. Curr Med Chem. 2008;15:1147-1153 (Pubitemid 351997804)
70. Sato K., Kimura S., Segawa H., et al. Cytotoxic effects of gammadelta T cells expanded ex vivo by a third generation bisphosphonate for cancer immunotherapy. Int J Cancer. 2005;116:94-99 (Pubitemid 40827760)
71. Caccamo N., Meraviglia S., Scarpa F., et al. Aminobisphosphonate- activated gammadelta T cells in immunotherapy of cancer:Doubts no more. Expert Opin Biol Ther. 2008;8:875-883 (Pubitemid 352007000)
72. Bonneville M., Scotet E. Human Vgamma9Vdelta2 T cells:Promising new leads for immunotherapy of infections and tumors. Curr Opin Immunol. 2006;18:539-546 (Pubitemid 44311448)
73. Cendron D., Ingoure S., Martino A., et al. A tuberculosis vaccine based on phosphoantigens and fusion proteins induces distinct gammadelta and alphabeta T cell responses in primates. Eur J Immunol. 2007; 37:549-565 (Pubitemid 46915593)
74. Ali Z., Yan L., Plagman N., et al. Gammadelta T cell immune manipulation during chronic phase of simian-human immunodeficiency virus infection [corrected] confers immunological benefits. J Immunol. 2009; 183:5407-5417
75. Poccia F., Gioia C., Martini F., et al. Zoledronic acid and interleukin-2 treatment improves immunocompetence in HIV-infected persons by activating Vgamma9Vdelta2 T cells. AIDS. 2009;23:555-565
76. Poccia F., Gougeon M., Agrati C., et al. Innate T-cell immunity in HIV infection:The role of Vgamma9Vdelta2 T lymphocytes. Curr Mol Med. 2002;2:769-781 (Pubitemid 35390312)
77. Lopez R. Human gammadelta-T cells in adoptive immunotherapy of malignant and infectious diseases. Immunol Res. 2002;26:207-221 (Pubitemid 35177498)
78. Gougeon M., Malkovsky M., Casetti R., Agrati C., Poccia F. Innate T cell immunity to HIV-infection. Immunotherapy with phosphocarbohydrates, a novel strategy of immune intervention? Vaccine. 2002; 20:1938-1941 (Pubitemid 34450791)
79. Poccia F., Malkovsky M., Gougeon M., et al. Gammadelta T cell activation or anergy during infections:The role of nonpeptidic TCR ligands and HLA class I molecules. J Leukoc Biol. 1997;62:287-291 (Pubitemid 27431598)
80. Nunnari G. Do Vgamma2Vdelta2 T cells influence HIV disease progression? Clin Infect Dis. 2008;46:1473-1475 (Pubitemid 351589955)
81. Poles M., Barsoum S., Yu W., et al. Human immunodeficiency virus type 1 induces persistent changes in mucosal and blood gammadelta T cells despite suppressive therapy. J Virol. 2003;77:10456-10467 (Pubitemid 37129690)
82. Nilssen D., Muller F., Oktedalen O., et al. Intraepithelial gamma/delta T cells in duodenal mucosa are related to the immune state and survival time in AIDS. J Virol. 1996;70:3545-3550 (Pubitemid 26157334)
83. Gan Y., Lui S., Malkovsky M. Differential susceptibility of naive and activated human gammadelta T cells to activation-induced cell death by T-cell receptor cross-linking. Mol Med. 2001;7:636-643 (Pubitemid 34175292)
84. Imlach S., Leen C., Bell J., Simmonds P. Phenotypic analysis of peripheral blood gammadelta T lymphocytes and their targeting by human immunodeficiency virus type 1 in vivo. Virology. 2003;305:415-427 (Pubitemid 36259676)
85. Lusso P., Garzino-Demo A., Crowley R., Malnati M. Infection of gamma/ delta T lymphocytes by human herpesvirus 6:Transcriptional induction of CD4 and susceptibility to HIV infection. J Exp Med. 1995;181: 1303-1310
86. Kosub D., Durudas A., Lehrman G., et al. Gamma/Delta T cell mRNA levels decrease at mucosal sites and increase at lymphoid sites following an oral SIV infection of macaques. Curr HIV Res. 2008;6:520-530
87. Favre D., Lederer S., Kanwar B., et al. Critical loss of the balance between Th17 and T regulatory cell populations in pathogenic SIV infection. PLoS Pathog. 2009;5:e1000295.
88. Brenchley J., Paiardini M., Knox K., et al. Differential Th17 CD4 T-cell depletion in pathogenic and nonpathogenic lentiviral infections. Blood. 2008;112:2826-2835
89. Cecchinato V., Trindade C., Laurence A., et al. Altered balance between Th17 and Th1 cells at mucosal sites predicts AIDS progression in simian immunodeficiency virus-infected macaques. Mucosal Immunol. 2008; 1:279-288 (Pubitemid 351850534)
90. Liu J., Pezeshki M., Raffatellu M. Th17 cytokines and host-pathogen interactions at the mucosa:Dichotomies of help and harm. Cytokine. 2009;48:156-160
91. Raffatellu M., Santos R., Verhoeven D., et al. Simian immunodeficiency virus-induced mucosal interleukin-17 deficiency promotes Salmonella dissemination from the gut. Nat Med. 2008;14:421-428 (Pubitemid 351499394)
92. Eberl M., Roberts G., Meuter S., et al. A rapid crosstalk of human gammadelta T cells and monocytes drives the acute inflammation in bacterial infections. PLoS Pathog. 2009;5:e1000308.
93. Douek D., Roederer M., Koup R. Emerging concepts in the immunopathogenesis of AIDS. Annu Rev Med. 2009;60:471-484
94. Goonetilleke N., Liu M.K., Salazar-Gonzalez J., et al. The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection. J Exp Med. 2009;206:1253-1272
95. Ferre A., Hunt P., Critchfield J., et al. Mucosal immune responses to HIV-1 in elite controllers:A potential correlate of immune control. Blood. 2009;113:3978-3989
96. Mehandru S., Poles M., Tenner-Racz K., et al. Primary HIV-1 infection is associated with preferential depletion of CD4+ T lymphocytes from effector sites in the gastrointestinal tract. J Exp Med. 2004; 200:761-770 (Pubitemid 39299462)
97. Brenchley J., Douek D. HIV infection and the gastrointestinal immune system. Mucosal Immunol. 2008;1:23-30.